The Food and Drug Administration has avowed Biolase Technology of San Clemente, in California clearance to vend its Waterlase laser therapy for root canal procedures on hard and soft tissue. The approval is the first by the FDA for a laser root canal and covers all enamel, dentin and pulpal removal as well as shaping of the root canal. The Waterlase is not a direct laser, the but alternatively furnishes optical energy to water, and the water particles themselves provide the cutting of dental hard tissue.
Use of the Waterlase may reduce the need for anesthesia and fewer instruments can be used for treatment, according to Biolase. Postoperatively, it may reduce pain, discomfort, swelling and the need for antibiotics.Dr. Jeffrey Hutter, chair of the ADA Council on Scientific Affairs and president of the American Association of Endodontists, said, "The ADA and the AAE are always interested in the introduction of new instruments and materials that may improve the quality of endodontic care provided to patients."
